Preimplantation genetic detection is a method which examines the embryos that are created using the process of in vitro fertilization. This facilitates the implantation of only selected fit embryos into the uterus thus making sure that a healthy baby is delivered. This prevents the carrying of genetic disorders into the family generations. The testing is done by a screening process wherein the healthy ones are frozen and stored.
Drivers and Restraints of Market
Due to the hectic, sedentary and non-active modern life, many couples are facing difficulties in conceiving naturally. The increasing pollution and the usage of chemicals in farming and animal husbandry sectors have greatly exacerbated infertility in the millennial generation. Some couples might also have genetic diseases that they might not wish to be passed down to their offsprings. In these cases, embryos that have been fertilized in vitro have the option of being examined to see if they contain any harmful genetic matter or any disease that either of the parents has. This advancement in science has allowed many couples to have children who might have otherwise not tried at all. The increasing occurrence of infertility around the world, growing support from public and private organizations in this field, rising medical facilities catering to patients with fertility issues, advancing technology in the field of genetics, awareness about chromosomal anomalies with growing age of mother are all the factors that can be attributed to the growth of preimplantation genetic testing market.
Ethical concerns regarding the doctors choosing which embryo might become a full-fledged human and which one might not are troubling some people. The increasingly expensive healthcare facilities are making sure the latest advancements in the field of medicine are accessible only to a few. Rising costs and lack of awareness are thus the two main restraints preventing the market from reaching its full potential.
Market Value and Growth
Preimplantation Genetic Testing Market is valued at USD xx billion in 2019 and is projected to grow at a Compound Annual Growth Rate (CAGR) of xx % during the forecast period to a net market size of USD xx billion in 2024.
The Preimplantation Genetic Testing Market is segmented based on by Procedure Type into Genetic Diagnosis and Genetic Screening.
Based on Technology, the market is segmented into NGS (Next Generation Sequencing), PCR (Polymerase Chain Reaction), FISH (Fluorescence in Situ Hybridization), CGH (Comparative Genomic Hybridization), and SNP (Single Nucleotide Polymorphisms).
Based on Products & Services, the market is segmented into Reagents & consumables, Instruments, Software & Services.
Based on Application, the market is segmented into Structural Chromosomal Abnormalities, Single Gene Disorders, X-Linked Disorders, HLA Typing, and Gender Identification. The Structural Chromosomal Abnormalities is further divided into Translocations, Deletions, Duplications, and Inversions.
Based on End User, the market is segmented into Fertility Clinics, Hospitals, and Research Laboratories.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. The top two markets in the world for Preimplantation Genetic Testing are North America and Europe. This can be attributed to the high average wage levels and minimal inequality in terms of access to quality healthcare. The market in the Asia Pacific despite being smaller than the top two markets is projected to increase with the highest rate during the forecast period of 2019-2024.
Some of the significant markets operating in the Global Preimplantation Genetic Testing Market are Illumina Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
Illumina Inc., a great company, was founded by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and, Mark Chee in the year 1998. The company mainly develops, manufactures and markets integrated systems for the analysis of genetic variation and testing. It was headed by Francis deSouza, who acted as its CEO and President. As of 2017 it had a total of 5,500 employees and reported net revenue of USD 2.752 billion.
Research Report Key Highlights
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Screening
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.2 Reagents and Consumables
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4.3 Structural Chromosomal Abnormalities
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End users
5.5.6 Market Attractiveness Analysis, By End users
5.5.7 Market Share Analysis, By End users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End user
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End user
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End user
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures